Form 4: Atea Pharmaceuticals Director Bruce Polsky Boosts Equity Stake with New RSU and Option Grants

Atea Pharmaceuticals, Inc. Director Bruce Polsky reported the acquisition of 29,600 shares of common stock through RSU conversion and new grants of 29,600 restricted stock units and 41,200 stock options.

Summary

• Bruce Polsky, a Director of Atea Pharmaceuticals, Inc. (AVIR), reported changes in his beneficial ownership of company securities.
• On June 20, 2025, Polsky acquired 29,600 shares of common stock at a price of $0.00, resulting from the conversion of previously vested restricted stock units.
• Following this transaction, Polsky's direct beneficial ownership of common stock increased to 95,206 shares.
• He also received new grants of 29,600 restricted stock units (RSUs) and 41,200 stock options on the same date.
• The newly granted RSUs will vest in a single installment on the earlier of the next annual meeting or the first anniversary of the grant date, subject to continued service.
• The newly granted stock options have an exercise price of $3.25 and will vest in 12 substantially equal monthly installments, becoming fully vested on the first anniversary of the grant date, also subject to continued service.
• The options have an expiration date of June 19, 2035.

Sentiment

Score: 7

Explanation: The document reports equity grants to a director, which is generally positive as it aligns management's interests with shareholders and incentivizes long-term commitment. There are no negative financial or operational disclosures.

Positives

• Director Bruce Polsky increased his direct beneficial ownership of common stock to 95,206 shares, indicating a stronger alignment of interests with shareholders.
• The grant of 29,600 new Restricted Stock Units (RSUs) and 41,200 stock options to a director suggests continued commitment and incentivization of key management.
• The vesting schedules for both RSUs and stock options are tied to continued service, promoting long-term retention of the director.

Negatives

• No specific negatives are identified in this Form 4 filing, as it primarily reports equity grants and conversions.

Risks

• The vesting of new restricted stock units and stock options is subject to the reporting person's continued service through the applicable vesting dates, meaning the benefits are contingent on ongoing employment or board membership.

Future Outlook

The document indicates future vesting events for the newly granted restricted stock units and stock options, contingent on the director's continued service. The RSUs are set to vest on the earlier of the next annual meeting or the first anniversary of the grant, while the stock options will vest monthly over the first year following the grant date.

Management Comments

• Restricted stock units convert into common stock on a one-for-one basis.
• The restricted stock units vest in a single installment on the earlier of (i) the date of the next annual meeting of the Issuer's stockholders occurring after the date of grant or (ii) the first anniversary of the date of grant, in each case, subject to the Reporting Person's continued service through the applicable vesting date.
• The option vests and becomes exercisable in twelve (12) substantially equal monthly installments following June 20, 2025, such that the option shall be fully vested on the first anniversary of the date of grant, subject to the Reporting Person's continued service through each such vesting date.
• The restricted stock units vested in full on June 20, 2025.

Industry Context

This Form 4 filing reflects standard equity compensation practices for directors in the biotechnology or pharmaceutical industry, aiming to align executive interests with long-term shareholder value. Such grants are common mechanisms to incentivize leadership and retain talent in a competitive sector like pharmaceuticals, where long development cycles and regulatory hurdles necessitate sustained commitment.

Comparison to Industry Standards

• The grant of restricted stock units (RSUs) and stock options to a director is a common practice in the pharmaceutical and biotechnology industries, aligning director incentives with company performance.
• The vesting schedules, particularly the one-year vesting for RSUs (either at the next annual meeting or first anniversary) and monthly vesting over one year for options, are typical for director equity compensation, promoting retention and long-term commitment.
• The exercise price of $3.25 for the stock options, being at or above the current market price at the time of grant (implied by $0 acquisition cost for RSUs), is standard for incentive options.
• While specific comparable companies or projects are not detailed in this filing, the structure of these grants is consistent with compensation packages observed at similar-stage biotech firms focused on drug development.

Related Party Transactions

• The acquisition of common stock, restricted stock units, and stock options by Director Bruce Polsky represents compensation from the company, which is a standard related-party transaction for executive and board members.

Stakeholder Impact

• Shareholders: The increased equity stake and new grants for a director can be seen positively as it aligns the director's financial interests with the long-term performance of the company, potentially leading to more shareholder-friendly decisions.
• Employees: While not directly impacted, such compensation structures for leadership can signal stability and a commitment to long-term growth, which indirectly benefits employees.

Next Steps

• The newly granted Restricted Stock Units are expected to vest on the earlier of the next annual meeting of stockholders or the first anniversary of the grant date (June 20, 2026).
• The newly granted stock options will vest in 12 substantially equal monthly installments following June 20, 2025, becoming fully vested on June 20, 2026.

Key Dates

Keywords

Atea Pharmaceuticals, AVIR, SEC Form 4, Insider Trading, Beneficial Ownership, Restricted Stock Units, RSUs, Stock Options, Equity Grant, Director Compensation, Bruce Polsky